Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies.
Eugenia Martinez-HernandezMar GuaspAnna García-SerraEstibaliz MaudesHelena AriñoMaria SepúlvedaThaís ArmanguéAna P RamosTamir Ben-HurTakahiro IizukaAlbert SaizFrancesc GrausJosep DalmauPublished in: Neurology (2020)
Between 4% and 7.5% of patients with anti-NMDAR encephalitis have concurrent glial-Ab or NS-Ab. Some of these antibodies (MOG-Ab, AQP4-Ab, NS-Ab) confer additional clinical-radiologic features and may influence prognosis.